XT
VVOS icon

XTX Topco’s Vivos Therapeutics VVOS Stock Holding History

XTX Topco’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,117
Closed -$29.6K – 4762
2026
Q1 		$29.6K Buy
+25,117
New +$40.3K ﹤0.01% 3456
2025
Q3 		– Sell
-20,528
Closed -$64.9K – 3352
2025
Q2 		$64.9K Buy
+20,528
New +$51.8K ﹤0.01% 1968

Other funds holding VVOS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

XTX Topco's VVOS Position: Q2 2026 in Review

XTX Topco sold out of Vivos Therapeutics (VVOS) in Q2 2026, closing a stake of 25,117 shares — an estimated $29.6K sold.

XTX Topco first reported a position in VVOS in Q2 2025 and held it in 2 quarters. The position peaked at $64.9K in Q2 2025. 23 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

  • XTX Topco reported no remaining Vivos Therapeutics position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 25,117 Vivos Therapeutics shares in Q2 2026, an estimated $29.6K.
  • XTX Topco first reported a position in Vivos Therapeutics in Q2 2025 and held it in 2 quarters.
  • XTX Topco's Vivos Therapeutics position peaked at $64.9K in Q2 2025.
  • 23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.